The main aims of our single center study were to (1) identify variants of the SLC2A9 and SLC22A12 genes, (2) determine their frequency compared to the European population, and (3) to evaluate the variants in relation to clinical, biochemical, and genetic data of a cohort with primary hyperuricemia and gout. This evidence concerns the gene SLC22A12 and gout.